chevron_leftBack
As of 16 June 2026, Absci Corp. has a market cap of $732.16M USD, ranking #12682 globally and #2382 in the United States.
It ranks #1158 in the Healthcare sector, and #213 in the Biotechnology industry.
Key Stats
Market Cap
$732.16MUSD
Enterprise Value
$622.7MUSD
Revenue (TTM)
$2.8MUSD
EBITDA (TTM)
-$112.98MUSD
Net Income (TTM)
-$115.18MUSD
PS Ratio
272.0
PB Ratio
3.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Sean McClain
open_in_new
Employees
140
Founded
2011
IPO
22 Jul 2021
Website
absci.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.1% | 28% | 69% | 60% | 7% | 48% |
News
Loading...
ABSI Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ABSI
Absci Corp
ISIN: US00091E1091
Shares Out.:
Shares Outstanding:
155.905M1
Shares Float:
133.281M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
4.71 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Absci Corp.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
25K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
22K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
4K%
|
-
|
|
NYSE: IQV
|
$26.3B
3K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
3K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
2K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.99B
6K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$45.02B
6K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.64B
6K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.46B
6K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.23B
4K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
3K%
|
-
|
chevron_leftBack